SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Actuate Therapeutics to Present Preclinical Elraglusib Data at ENA 2026

Actuate Therapeutics says it will present preclinical data on the antitumor and immune activation activity of its elraglusib oral tablet in advanced melanoma models at ENA 2026.

ACTU

Related stories